<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225561</url>
  </required_header>
  <id_info>
    <org_study_id>P130946</org_study_id>
    <secondary_id>2014-002010-24</secondary_id>
    <nct_id>NCT02225561</nct_id>
  </id_info>
  <brief_title>SNPeCPR In Cardiac Arrest REsuscitation</brief_title>
  <acronym>SICARE</acronym>
  <official_title>SNPeCPR Pour la prIse en Charge Des Arrêts CaRdiaques Extrahospitaliers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 50,000 patients are victims of out of hospital cardiac arrest every year in&#xD;
      France. Despite cardiopulmonary resuscitation (CPR) and many studies on the topic&#xD;
      resuscitation survival after cardiac arrest remains low (1-8%) and has not changed&#xD;
      significantly over the past five decades.It has recently been shown that the combination of&#xD;
      different non-invasive therapies, cardiopulmonary resuscitation with mechanical CPR with&#xD;
      automated compression / decompression and an impedance threshold device, can increase the&#xD;
      rate of return of spontaneous circulation and short and long term survival after cardiac&#xD;
      arrest.We propose to study a new cardiopulmonary resuscitation called SNPeCPR (Sodium&#xD;
      nitroprusside enhanced cardiopulmonary resuscitation), which includes two components:a) a&#xD;
      mechanical component: cardiopulmonary resuscitation with automated mechanical external chest&#xD;
      compression and an impedance threshold deviceb) a pharmacological component: sodium&#xD;
      nitroprusside, an effective arterial vasodilator that decrease vascular resistance, and&#xD;
      improve flow in vital organs.Our hypothesis is that SNPeCPR should improve the return of&#xD;
      spontaneous circulation rate during cardiac arrest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. OBJECTIVES The objective of this study is to demonstrate the superiority of Sodium&#xD;
           nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR) on optimized standard&#xD;
           cardiopulmonary resuscitation.&#xD;
&#xD;
           SNPeCPR includes two components:&#xD;
&#xD;
             1. a mechanical component: cardiopulmonary resuscitation with automated mechanical&#xD;
                external chest compression and an impedance threshold device&#xD;
&#xD;
             2. a pharmacological component: sodium nitroprusside, an effective arterial&#xD;
                vasodilator that decreasing vascular resistance, facilitates flow elevation in&#xD;
                vital organs.&#xD;
&#xD;
           1.1. Main Objective : Assess the interests of the administration of sodium nitroprusside&#xD;
           during enhanced cardiopulmonary resuscitation.&#xD;
&#xD;
           1.2. Secondary Objectives : To evaluate the effect of sodium nitroprusside on various&#xD;
           parameters before and after the return of spontaneous circulation.&#xD;
&#xD;
           1.3. Outcome Measures : In this declaration, all the criterions measures before ROSC&#xD;
           have been note as t=0 minute.&#xD;
&#xD;
           For the elements were the timeframe is a variable, ICU and hospital discharge, they have&#xD;
           been declare at 1 and 2 weeks respectively.&#xD;
&#xD;
        2. NAME AND DESCRIPTION OF THE INVESTIGATIONAL DRUG Sodium nitroprusside (SNP) is a potent&#xD;
           vasodilator that we will use in cardiac arrest to optimize vital organs perfusion. The&#xD;
           purpose of CPR is to provide oxygenated blood to vital organs that are most susceptible&#xD;
           to ischemic insult (brain and heart). Since the mechanical combination (cardiopulmonary&#xD;
           resuscitation with automated mechanical external chest compression and an impedance&#xD;
           threshold device) provides excellent perfusion pressure, the flow should be optimized&#xD;
           pharmacological with vasodilation. The SNP reduces arterial vasoconstriction and&#xD;
           enhances microcirculation. Furthermore, SNP significantly reduces vascular resistance&#xD;
           and decreases cardiac ejection afterload. Therefore, SNPeCPR can significantly increase&#xD;
           the flow of blood and optimize carotid and coronary flow.&#xD;
&#xD;
        3. PROCEDURE During cardiac arrest resuscitation, patients will be included in the study&#xD;
           after the investigator has verified the inclusion and non-inclusion criterion. A sealed&#xD;
           box containing SNP or the placebo will then be open in the increasing numbers of&#xD;
           randomization list.&#xD;
&#xD;
           Whatever the allocated treatment (nitroprusside or Placebo [5% glucose solution]),&#xD;
           cardiopulmonary resuscitation protocol will be realize as recommended by the 2010&#xD;
           European Resuscitation Council and described as follows:&#xD;
&#xD;
             -  cardiopulmonary resuscitation will be performed continuously without posing for&#xD;
                control pulse until the first defibrillation attempt. As soon as possible manual&#xD;
                CPR will be replace by automated mechanical external chest compression (LUCAS® -&#xD;
                Lund University Cardiopulmonary Assist System) and an impedance threshold device&#xD;
                (ResQPOD®).&#xD;
&#xD;
             -  placement of a peripheral intravenous (IV) or intraosseous (IO) line. This&#xD;
                placement will be privileged to intubation,&#xD;
&#xD;
             -  when the peripheral intravenous or intraosseous line is set, 1.96 mg sodium&#xD;
                nitroprusside (SNP) / placebo will be injected, followed by injection of 10 ml&#xD;
                saline for intravenous flush (t = 0 minutes).&#xD;
&#xD;
             -  1 mg of epinephrine will be injected at t = 2 minutes,&#xD;
&#xD;
             -  an external electric shock (EEC) will be realized at t = 3 minutes when the&#xD;
                electric heart type allows it (ventricular fibrillation or ventricular&#xD;
                tachycardia),&#xD;
&#xD;
             -  0.98 mg sodium nitroprusside / placebo will be injected at t = 4 minutes, followed&#xD;
                by an injection of 10 ml of saline for intravenous flush.&#xD;
&#xD;
             -  1 mg adrenaline will be injected at t = 7 minutes, the injection will be repeated&#xD;
                every 5 minutes until return of spontaneous circulation or ending of the&#xD;
                resuscitation decided by the emergency physician.&#xD;
&#xD;
             -  an external electric shock (EEC) will be realized at t = 6 minutes when the&#xD;
                electric heart type allows, then external shock will be repeated every 3 minutes&#xD;
                until return of spontaneous circulation or ending of the resuscitation decided by&#xD;
                the emergency physician.&#xD;
&#xD;
           During that resuscitation the following parameters will be collected:&#xD;
&#xD;
             -  The type of cardiac arrest (place of cardiac arrest [home, public place, stadium&#xD;
                …], cardiac arrest before a witness or prompt rescue team, cardiac massage by the&#xD;
                witness or prompt rescue team, durations between collapse and the start of&#xD;
                resuscitation, non-specialized / specialized resuscitation, defibrillation shock by&#xD;
                the witness or prompt rescue team), ETCO2, blood pressure and SpO2.&#xD;
&#xD;
             -  the initial electrical rhythm (defined by ECG) by the mobile intensive care unit&#xD;
                (MICI) and ECG 5 minutes after return of spontaneous circulation.&#xD;
&#xD;
             -  arterial blood gas lactate&#xD;
&#xD;
             -  troponin (24 hours after ROSC)&#xD;
&#xD;
             -  liver function (24 hours after ROSC)&#xD;
&#xD;
             -  creatinine (24 hours after ROSC)&#xD;
&#xD;
             -  echocardiography (4 and 24 hours after ROSC)&#xD;
&#xD;
        4. EXPECTED DURATION OF PARTICIPATION OF PEOPLE AND DESCRIPTION OF THE TIMING AND DURATION&#xD;
           OF THE RESEARCH.&#xD;
&#xD;
           Duration of intervention: 4 minutes Inclusion time: 30 months duration of participation&#xD;
           (+ monitoring treatment): 6 months Total duration of the study: 3 years&#xD;
&#xD;
        5. RANDOMIZATION Randomization will be realized by block and will be stratified by center.&#xD;
           The boxes are numbered and contain drugs specified by the randomization arm.&#xD;
           Randomization will be done by assigning at each inclusion a box taken in order of&#xD;
           increasing numbers of the randomization list. The randomization list will be established&#xD;
           under the responsibility of the clinical research unit.&#xD;
&#xD;
        6. MONITORING COMMITTEE A monitoring committee will conduct an interim analysis after the&#xD;
           inclusion of 50% and 75% of patients and will decide to stop or continue the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinuation of the experimental treatment being tested&#xD;
  </why_stopped>
  <start_date type="Actual">January 2, 2015</start_date>
  <completion_date type="Actual">January 2, 2018</completion_date>
  <primary_completion_date type="Actual">July 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of return of spontaneous circulation (ROSC)</measure>
    <time_frame>at 5 minutes</time_frame>
    <description>Rate of return of spontaneous circulation (ROSC) defined as a central pulse (carotid or femoral) palpable for more than 5 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ETCO2</measure>
    <time_frame>at 0, 5 and 60 minutes</time_frame>
    <description>ETCO2 (before ROSC, 5 and 60 min after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>at 5 and 60 min</time_frame>
    <description>at 5 and 60 min after ROSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>at 0, 5 and 60 minutes</time_frame>
    <description>ECG (before ROSC, 5 min after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>at 0, 5 and 60 minutes</time_frame>
    <description>SpO2 (before ROSC, 5 and 60 min after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gases with lactate</measure>
    <time_frame>at 0 and 5 minutes; 1, 4 and 24 hours</time_frame>
    <description>arterial blood gases with lactate (before ROSC, 5 min, 1, 4 and 24 hours after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin</measure>
    <time_frame>at 24 hours</time_frame>
    <description>troponin (24 hours after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>at 24 hours</time_frame>
    <description>liver function (24 hours after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>at 24 hours</time_frame>
    <description>creatinine (24 hours after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>at 4 and 24 hours</time_frame>
    <description>echocardiography (4 and 24 hours after ROSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1, 4 and 24 hours, 1 week, 2 weeks, 1 and 6 months</time_frame>
    <description>survival (1, 4 and 24 hours after ROSC, ICU and hospital discharge, 1 and 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological score</measure>
    <time_frame>1 week, 2 weeks, 1 and 6 months</time_frame>
    <description>neurological score (ICU and hospital discharge, 1 and 6 months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cardiopulmonary Arrest</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaco- mechanical optimization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mechanical optimization only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanical optimization only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmaco- mechanical optimization</intervention_name>
    <description>Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.&#xD;
As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:&#xD;
Using a &quot;pomping needle&quot; and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.&#xD;
The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.&#xD;
Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect.</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mechanical optimization only</intervention_name>
    <description>Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.</description>
    <arm_group_label>Mechanical optimization only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with out of hospital cardiac arrest&#xD;
&#xD;
          -  Age&gt; 18 years and &lt;75 years&#xD;
&#xD;
          -  Initial Rhythm: Ventricular fibrillation or ventricular tachycardia or pulseless&#xD;
             electrical activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  out of hospital cardiac arrest of non-cardiac origin:&#xD;
&#xD;
               -  trauma&#xD;
&#xD;
               -  anoxic, including drowning&#xD;
&#xD;
               -  hemorrhage,&#xD;
&#xD;
               -  overdose (drugs),&#xD;
&#xD;
               -  drug,&#xD;
&#xD;
               -  electric&#xD;
&#xD;
          -  Do Not Resuscitate Order,&#xD;
&#xD;
          -  obvious signs of clinical death (decomposition, cadaveric rigidity, decapitation)&#xD;
&#xD;
          -  recent sternotomy (&lt;6 months or recent scar)&#xD;
&#xD;
          -  Contraindications related to sodium nitroprusside&#xD;
&#xD;
               -  Women of childbearing age (between 18 and 55 years)&#xD;
&#xD;
               -  Other contra-indications will usually not known during resuscitation in case of&#xD;
                  presence of a relative rescue team must be searched: Hypothyroidism, Sulfuryl&#xD;
                  transferase deficiency (rhodanese Lang) currently recognized in patients with&#xD;
                  Leber optic atrophy, tobacco amblyopia or severe hepatic impairment.&#xD;
&#xD;
          -  Obesity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick PLAISANCE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SMUR - Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Schultz J, Segal N, Kolbeck J, Caldwell E, Thorsgard M, McKnite S, Aufderheide TP, Lurie KG, Yannopoulos D. Sodium nitroprusside enhanced cardiopulmonary resuscitation prevents post-resuscitation left ventricular dysfunction and improves 24-hour survival and neurological function in a porcine model of prolonged untreated ventricular fibrillation. Resuscitation. 2011 Dec;82 Suppl 2:S35-40. doi: 10.1016/S0300-9572(11)70149-6.</citation>
    <PMID>22208176</PMID>
  </reference>
  <reference>
    <citation>Schultz J, Segal N, Kolbeck J, McKnite S, Caldwell E, Yannopoulos D. Sodium nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR) improves vital organ perfusion pressures and carotid blood flow in a porcine model of cardiac arrest. Resuscitation. 2012 Mar;83(3):374-7. doi: 10.1016/j.resuscitation.2011.07.038. Epub 2011 Aug 22.</citation>
    <PMID>21864483</PMID>
  </reference>
  <reference>
    <citation>Schultz JC, Segal N, Caldwell E, Kolbeck J, McKnite S, Lebedoff N, Zviman M, Aufderheide TP, Yannopoulos D. Sodium nitroprusside-enhanced cardiopulmonary resuscitation improves resuscitation rates after prolonged untreated cardiac arrest in two porcine models. Crit Care Med. 2011 Dec;39(12):2705-10. doi: 10.1097/CCM.0b013e31822668ba.</citation>
    <PMID>21725236</PMID>
  </reference>
  <reference>
    <citation>Yannopoulos D, Matsuura T, Schultz J, Rudser K, Halperin HR, Lurie KG. Sodium nitroprusside enhanced cardiopulmonary resuscitation improves survival with good neurological function in a porcine model of prolonged cardiac arrest. Crit Care Med. 2011 Jun;39(6):1269-74. doi: 10.1097/CCM.0b013e31820ed8a6.</citation>
    <PMID>21358401</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiopulmonary resuscitation</keyword>
  <keyword>Nitroprusside</keyword>
  <keyword>Transthoracic</keyword>
  <keyword>Impedances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

